Introduction
Alterations of neurotransmitter receptors and their intracellular signal transduction cascades on serotonin (5-HT) and/or norepinephrine (NE) pathways are believed to play a direct role in the pathogenesis of depression 1, 2 or, alternatively, they could represent an indirect adaptative response to other neurochemical disturbances. [2] [3] [4] Presynaptic regulation of NE/5-HT release involves activity of several neurotransmitter receptors located on nerve terminals. Among them, ␣ 2 -adrenoceptors, -opioid, GABA B and cholinergic muscarinic M 2 /M 4 receptors, by acting as autoreceptors or heteroreceptors, contribute to the inhibition of neurotransmitter release. [5] [6] [7] In depressed suicide victims, high densities of brain ␣ 2 -adrenoceptors have been found in terminal areas of NE and 5-HT pathways [8] [9] [10] [11] [12] [13] and at the somatodendritic level of noradrenergic cells.
14 Many antidepressant treatments are able to modulate ␣ 2 -adrenoceptor density and/or function. Thus, chronic administration of antidepressant drugs reduces the density and activity of ␣ 2 -adrenoceptors in rat brain [15] [16] [17] [18] [19] and in platelets of depressed patients. 20, 21 Based on these observations, it has been suggested that patients with mood disorders might have an underlying disturbance of noradrenergic and/or serotonergic function, perhaps due to hyperactive ␣ 2 -adrenoceptor function. 22 ␣ 2 -Adrenoceptors are members of the G protein coupled receptors family. Activation of these receptors promotes a conformational change in the heterotrim-eric G-proteins from an inactive guanosine diphosphate (GDP)-bound oligomeric form to an active guanosine triphosphate (GTP)-bound monomeric form. The prototypical ␣ 2A -adrenoceptor of the human brain activates inhibitory G-proteins 23, 24 that dissociate into G ␣i -GTP and G ␤␥ components. These molecular events are assumed to also occur for many other receptors that couple with inhibitory G-proteins (G i /G o ) and, among them, 5-HT 1A serotonin receptors, -opioid receptors, GABA B receptors and M 2 /M 4 muscarinic cholinergic receptors. 25 In the last years, the immunodetection of G-proteins with specific antibodies has led to altered levels of the different G-protein subunits in the brain of subjects with mood disorders. 13, [26] [27] [28] [29] [30] Because the amount of G i -proteins and the density of mature ␣ 2 -adrenoceptors maintain an stoichiometric equilibrium, 23, [31] [32] [33] the debate persists as to whether the receptor or the G-protein have the greater role in the observed up-regulation of ␣ 2 -adrenoceptors in mood disorders.
Recently, a method ([ 35 S]GTP␥S binding) developed to assess receptor-dependent functional activity of Gproteins has been applied to postmortem human brain. 34, 35 Activation of receptors by selective agonists promotes the GDP/GTP exchange, which facilitates the binding of radiolabeled GTP analogues to the ␣ subunit of G-proteins, allowing a functional measure of receptor sensitivity. The present study was designed to directly evaluate the functional sensitivity of several brain neurotransmitter receptors, all of them coupled to inhibitory G i /G o -proteins, in a group of subjects with mood disorders who committed suicide and their matched controls. The receptor-independent functional activity of G i /G o -proteins was also examined and the levels of the different G-proteins were quantified in the same preparations. On the basis of previous postmortem data, it was hypothesized that any relevant upregulation of a given neurotransmitter receptor in the brain of suicide victims with mood disorders would be associated with a selective receptor-dependent hyperactivity of G i /G o -proteins in response to a specific agonist.
Subjects and methods

Subject selection and brain samples
Human brains were obtained at autopsies performed in the Forensic Anatomical Institute, Bilbao, Spain, and the Institute of Forensic Medicine, Geneva, Switzerland. The study was developed in compliance with policies of research and ethical review boards for postmortem brain studies (Basque Institute of Legal Medicine, Bilbao, and Department of Psychiatry, University of Geneva, Geneva). A total of 245 consecutive brains, from subjects in whom the medical examiner had determined that suicide was the cause of death, were collected from May 1990 to December 1998. One subject with a previous diagnosis of bipolar disorder who died in a motor vehicle accident (case 9 in Table 1 ) was also included, although suicide was not the cause of death. Deaths recorded as suicide were subjected to retrospective careful searching for previous medical diagnosis and treatment using examiner's information and records of hospitals and mental health centers. After searching of antemortem information was fulfilled, 29 subjects had met criteria of major depression (n = 22), bipolar disorder (n = 6) or dysthymic disorder (n = 1), according to the Diagnostic and Statistical Manual of Mental Disorders (DSM-III-R). 36 One of the suicide victims with major depression also had a comorbid diagnosis of dysthymia. Another suicide victim who showed diagnostic criteria for major depression and alcohol abuse and dependence was excluded from the study. Thus, the definitive group of cases with mood disorders included 28 subjects (27 suicide victims and one bipolar patient accidentally dead, see above). The suicide victims died by trauma due to a fall from a height (n = 11), drug overdose (n = 5), gunshot wound (n = 4), hanging (n = 3), drowning (n = 3), and caustic ingestion (n = 1). The demographic characteristics (gender, age, postmortem delay) and the psychiatric diagnoses and treatments of the mood disorder group are summarized in Table 1 . Four of the 28 cases had been included in previous radioligand binding studies of ␣ 2 -adrenoceptors 9, 12 and the other five cases had been used for immunoblot detection of G-proteins and ␣ 2A -adrenoceptors. 13 A toxicological screening (quantitative assays for antidepressants, other psychotropic drugs and ethanol) was performed on blood, urine, liver and gastric content samples of 21 cases. The rest of the suicide victims (seven cases) were medicated at the time of death and apparently showed good compliance with treatments. All subjects who were drug-free shortly before death (as revealed by the absence of prescriptions in medical histories) also gave negative results in the toxicological screening. The results of the toxicological testing are listed in Table 1 . The toxicological assays were performed at the National Institute of Toxicology, Madrid, Spain, or at the Toxicology Unit, Institute of Forensic Medicine, Geneva, using a variety of standard procedures including radioimmunoassay, enzymatic immunoassay, highperformance liquid chromatography and gas chromatography-mass spectrometry.
Over the same period of time (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) , 330 brains of non-suicide potential controls were consecutively obtained at autopsy from subjects who died suddenly, mainly from violent causes. A retrospective searching for antemortem clinical history in these control subjects was also performed. Drug and alcohol toxicological screening was carried out on blood and urine samples of most of the subjects. Controls for the present study (n = 28) were chosen among the collected brains on the basis, whenever possible, of the following cumulative criteria: (1) negative medical information on the presence of neuropsychiatric disorders or drug abuse; (2) appropriate gender, age (normally ± 10 years) and postmortem delay (normally ±12 hours, except in two cases) to match each subject in the suicide group; (3) sudden and unexpected death (motor vehicle accidents, n = 22; cardiac arrest, n = 4; accidental asphyxia, n = 1; sport accident, n = 1); and (4) toxicological . Blood levels of ethanol (ETH) are expressed in g l −1 screening of psychotropic drugs with negative results except for ethanol. The past medical records of the selected controls revealed the presence of subjects with cardiomyopathy (n = 1), arterial hypertension (n = 1), fatty liver (n = 1) and diabetes mellitus (n = 1). Ethanol was detected in some control subjects (1.2 ± 0.5 g l −1 ; n = 4). Toxicological screening in control subjects was not performed in nine cases. The tissue storage period before assays did not differ between suicide victims (36 ± 5 months) and controls (32 ± 4 months). The definitive pairs of subjects (suicides and their respective matched controls) are shown in Table 1 .
Specimens of prefrontal cortex (Brodmann's area 9) were dissected (0.5-1 g tissue) on an ice-cooled surface and immediately stored at −70°C until membrane preparation.
Membrane preparation
After thawing of the cortical specimens, membranes (P 2 fractions) were obtained as described previously. 34 The samples were processed under code to blind the diagnostic group of the subjects. Cortical tissues were homogenized (1:30 weight/volume dilution) in an icecold Tris buffer (50 mmol l −1 Tris hydrochloride, 3 mmol l −1 magnesium chloride, 1 mmol l −1 dithiothreitol, 1 mmol l −1 ethyleneglycoldiaminetetracetic acid, pH 7.4) containing 0.25 mol l −1 sucrose. After centrifugation (1000 × g, 5 min, 4°C), the supernatants were saved and recentrifuged at 40 000 × g for 10 min at 4°C. The pellet was washed twice with 10 ml of ice-cold Tris homogenization buffer and recentrifuged at 40 000 × g. The resultant pellet was resuspended in 1-ml aliquots, recentrifuged, and after discharge of the supernatant, it was stored at −70°C for binding assays, immunoblot analyses and protein content determinations.
[ 35 S]GTP␥S binding assays
The functional activity of G proteins was assessed by the [ 35 S]GTP␥S binding assay as described previously. 34 The method is based on the ability of the radiolabeled GTP analog termed sulfur 35 labeled guanosine-5′-O-(␥-thio)-triphosphate ([ Additionally, the GDP/[
35 S]GTP␥S exchange on inhibitory G i /G o -proteins may also be promoted by the peptide mastoparan, 37, 38 which acts directly on the ␣ subunit allowing the evaluation of G-proteins activity in a receptor-independent manner ( Figure 1 ). For these binding assays, aliquots of membrane preparations were thawed, resuspended at 80 g ml −1 of protein concentration and incubated with shaking at 30°C for 2 h in Tris incubation buffer (50 mmol l ) was used to determine receptor-independent stimulation of [ 35 S]GTP␥S binding. 37, 38 The incubations were terminated by diluting the samples with incubation buffer, and membrane-bound [ 35 S]GTP␥S was separated by rapid filtration under vacuum through glass fiber filters. After separation of the bound and free radioligand, the filters were rinsed twice with ice-cold incubation buffer, transferred to minivials containing liquid scintillation cocktail and counted for radioactivity (Packard model 2200CA). The assays were carried out in a paired design. Thus, in a given experiment, aliquots of one suicide victim were processed and incubated in parallel with the previously matched control. In this manner, concentration-response curves to each receptor agonist and to mastoparan were always performed in one suicide victim and one control subject under the same experimental conditions. Aliquots of the same membrane preparations were used in all experiments performed for each subject.
Immunoblot assays
The relative levels of G ␣i1/2 -, G ␣i3 -, G ␣o -, and G ␣s -proteins in cortical membrane preparations were assessed by Western blotting according to previously described methods. 13, 39 Briefly, aliquots of the prepared membranes were loaded on a 10% polyacrylamide gel (BioRad Laboratories, Hercules, CA, USA) and submitted to sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were immediately transferred to nitrocellulose membranes and incubated in blocking solution 39 for 1 h at room temperature. Then, the membranes were incubated in blocking solution containing the primary antibody: anti G ␣i1/2 (dilution 1:7000), anti G ␣i3 (1:3000), anti G ␣o (1:4000), and anti G ␣s (1:3000), followed by the secondary antibody, horseradish peroxidase-linked donkey antirabbit IgG at 1:5000 dilution. The nitrocellulose membranes were stripped and ␣-tubulin was detected in the same membrane using an anti ␣-tubulin antibody (1:3000) and sheep antimouse IgG as secondary antibody (1:5000). Immunoblotting was detected with an enhanced chemiluminiscence (ECL) Western blot detection system (Amersham, Bucks, UK), followed by exposure to AGFA film for 1-10 min. Films were scanned in an image analyzer using the NIH-IMAGE software (Bethesda, MA, USA). For the quantification of G-proteins and ␣-tubulin, duplicate problem samples (suicide victims and their matched controls), containing 3-4 g of total protein, were evaluated using standard curves, all loaded on the same gel. 39 This quantification procedure was repeated at least twice in different gels, for a total of four measurements for each subject sample. In a given gel, the relative amount of G-proteins of two suicide victims and their corresponding matched controls were quantified in a coded blind manner as problem samples together with the standard curve. The optical density of each G ␣ -protein sample was corrected for the optical density of the corresponding ␣-tubulin band. The intra-assay and inter-assay coefficients of variation were in the range 0.3-1% and 10-19%, respectively.
Analyses of data Data of [
35 S]GTP␥S binding stimulations are expressed as the maximal net stimulation (E max ) (stimulated minus basal levels) expressed in fmol mg −1 protein. Nonlinear regression analysis was performed on individual concentration-response curves of the agonistand mastoparan-induced stimulations (Prism, GraphPad Software, San Diego, CA, USA). The concentration of each drug that elicited half-maximal effect (EC 50 ) was obtained and normalized as −log EC 50 value to be compared. 40 Data are expressed as mean values ± standard error of the mean (SEM). Differences of [ 35 S]GTP␥S binding parameters between suicide and control populations were assessed by the unpaired Student's t-test. The level of significance was chosen at P = 0.05.
In immunoblot assays, the theoretical amount of protein in a problem sample (PT) was obtained by interpolation of the integrated optical density (IOD) value 5 -ol]-enkephalin), 8-OH-DPAT ((±)-8-hydroxy-2-(di-n-propylamino)tetralin) and other reagents were from Sigma Chemical Co (St Louis, MO, USA). Anti G ␣ -protein polyclonal antisera raised against specific C-terminal peptides were purchased from Dupont NEN. Anti ␣-tubulin monoclonal antibody (clone DM 1A) was from Sigma. Secondary antibodies were from Amersham.
Results
There were no significant differences in basal levels of [ 35 S]GTP␥S binding between the group of suicide victims with mood disorders and the control group (t = 0.61; df = 54; P = 0.55) ( Table 2 ). Analyses of covariance (ANCOVA) did not detect any effect of age (F 1,52 = 0.68; P = 0.41), postmortem delay (F 1,52 = 0.25; P = 0.62), or group differences (F 1,52 = 0.40; P = 0.53) on basal levels of [
35 S]GTP␥S binding.
Activation of G-proteins through ␣ 2 -adrenoceptors
The stimulation of the [ (Table 2) . Thus, the mean concentration-response curve for this agonist in the suicide group was shifted to the left when compared to that obtained in the control group (Figure 2) . (Figure 3) . Interestingly, the three suicide cases in which no potentiation was observed were subjects who had died by a drug overdose mechanism. The maximal stimulations of [ 35 S]GTP␥S binding induced by the ␣ 2 adrenoceptor agonist were not different between suicide victims with mood disorders and control subjects (Table 2; Figure 2) . No age or postmortem delay effects were observed in the separate ANCOVAs for each [ 35 S]GTP␥S binding parameter (normalized EC 50 , E max ) of the stimulation by UK14304 (data not shown). In this type of analysis, the differences between suicide victims and controls for the ␣ 2 -adrenoceptor-mediated sensitivity (EC 50 ) were maintained (F 1,52 = 8.95; P = 0.004) whereas the maximal stimulations (E max ) did not differ between groups (F 1,52 = 0.62; P = 0.44).
In the logistic regression analysis model, the only factor associated with suicide victims was the normalized EC 50 parameter. Odds ratio values reflected a selective and strong association between subjects displaying low EC 50 values for the ␣ 2 adrenoceptor agonist UK14304 and their presence in the suicide group (Table 3) . 
Activation of G-proteins through 5-HT 1A serotonin receptors
The stimulation of the [ 35 S]GTP␥S binding by the 5-HT 1A serotonin receptor agonist 8-OH-DPAT resulted in biphasic concentration-response curves (Figure 2 ). The sensitivity of the high-affinity (EC 50 high) and the low-affinity (EC 50 low) components were similar in suicide victims with mood disorders and control subjects ( Table 2 ). The individual matched comparison of normalized EC 50 high values displayed the absence of differences between groups (Figure 3) . The maximal stimulations of [ 35 S]GTP␥S binding induced by the 5-HT 1A serotonin receptor agonist were similar in suicide victims and controls (Table 2; Figure 2 ). Also the proportions of high-and low-affinity components were similar in both groups (Table 2) . Consequently, the mean concentration-response curves for the agonist 8-OH-DPAT in suicide victims and controls were almost identical ( Figure 2) . No association between parameters of the [ 35 S]GTP␥S binding stimulation by 8-OH-DPAT and the inclusion in the suicide or control groups was observed (Table 3 ). Figure 4) . Similarly, the maximal stimulations induced by DAMGO and baclofen were also unchanged in suicide victims when compared to matched controls (Table 2; Figure 4) . Consequently, the mean concentration-effect curves for both agonists in suicide victims did not differ from those obtained in controls (Figure 4) . The sensitivity and maximal stimulation of (Table 3) .
Activation of G-proteins through
Receptor-independent activation of G-proteins
To test whether supersensitivity of the [ 35 S]GTP␥S binding to the agonist UK14304 represents a receptordependent or an enhanced intrinsic activity of G-proteins, direct activation of the G-protein by mastoparan was performed in a new set of assays with the same subjects ( Figure 1 ). As shown in Table 4 , basal levels Molecular Psychiatry
of [
35 S]GTP␥S binding were similar to those obtained in previous conditions. The peptide mastoparan displayed concentration-response curves with similar sensitivity (EC 50 values) in suicide victims with mood disorders and in control subjects ( Table 4 ). The maximal stimulations elicited by mastoparan did not differ between suicide victims and controls (Table 4 ). The separate ANCOVA analyses for each [ 35 S]GTP␥S binding parameter (normalized EC 50 , E max ) did not show any significant influence of age or postmortem delay on the previous findings (data not shown).
Immunodensities of G-proteins and ␣-tubulin
In order to confirm that the observed changes in [ 35 S]GTP␥S binding were not related to increased amount of G-proteins in suicide victims, G-protein densities were quantified by immunoblot assays. The levels of the G ␣i1/2 -(t = 0.83; df = 54; P = 0.41), G ␣i3 -(t = 0.49; df = 54; P = 0.63), G ␣o -(t = 0.84; df = 54; P = 0.41) and 52 KDa G ␣s -(t = 0.94; df = 54; P = 0.35) proteins in brains of suicide victims were not different from those in controls ( Figure 5 ). No differences of ␣-tubulin levels were observed between suicide victims (102 ± 3%, n = 28) and controls (99 ± 3%, n = 28).
Effect of psychotropic drug treatments
The suicide victims in whom the toxicological screening confirmed the absence of treatment with psychotropic drugs other than benzodiazepines and alcohol (cases 4, 5, 6, 12, 13, 14, 18, 21, 24, 25, 26 and 27 in Table 1 ) were compared with the rest of suicide victims. There were no significant differences between ), but the difference (1.6-fold) did not reach statistical significance (normalized EC 50 : t = 1.39; df = 26; P = 0.18). No significant effect of drug treatment was observed on the density of the different G-proteins.
Effect of diagnosis
Because of the important presence of bipolar disorders among the group of suicide victims with mood disorders, the [
35 S]GTP␥S binding data and G-protein densities were further analyzed in bipolar disorders vs matched controls, and in major depression vs matched controls. The overall supersensitivity of ␣ 2 -adrenoceptor-mediated stimulations was maintained although it remained statistically significant in major depression (EC 50 = 0.47 ± 0.14 mol l 
Discussion
The present study was designed to evaluate pathophysiological alterations in the postmortem brain of subjects with mood disorders who committed suicide. A logistic regression model was also applied to the data in order to examine possible factors that might influence the results in this matched case-control study design. An ␣ 2A -adrenoceptor functional supersensitivity was found in prefrontal cortex whereas 5-HT 1A serotonin, -opioid, GABA B , and muscarinic cholinergic receptor activities were not altered.
Depression is the most important risk factor for suicide and, therefore, analysis of brain samples from suicide victims represents a widely used approach to study neurochemical alterations in mood disorders. [41] [42] [43] The main limitation of the study is that subjects committing suicide represent a subset of the total population with mood disorders and therefore, it is not possible to exclude the role of suicide in producing the changes herein observed. A control group based on suicide victims with other neuropsychiatric diseases different from mood disorders could have been considered to blind the case-control status of the subjects. However, the multiple psychotropic drug treatments in subjects with established psychiatric disorders would have added new potential confounding factors to the design. Furthermore, a bias for the present results based on the presence of suicide is unlikely because previous studies have demonstrated that biochemical alterations of brain ␣ 2 -adrenoceptor density are selectively found in suicide victims with major depression but not in suicide victims with other diagnoses. 9 The receptor activation induced by selective agonists promotes the exchange of GDP by GTP (or its analogue GTP␥S) (Figure 1 ) allowing the functional examination of G-protein coupled receptors in postmortem brain tissues. 34, 35 Thus, the displacement to the left (decreased EC 50 Besides receptor supersensitivity, changes in receptor-activated [ 35 S]GTP␥S binding could reflect the presence of an increased amount of G proteins. The data presented show that the receptor-independent activation of guanine nucleotide exchange on G i /G o -proteins induced by mastoparan was not altered in the sample of suicide victims. Furthermore, the immunoreactive levels of G-proteins in the same membrane preparations did not show significant changes in suicide victims when compared to control subjects. Therefore, the alternative hypothesis of a primary alteration in G-proteins was rejected based on these data.
Molecular Psychiatry
The finding of an enhanced functional activity of ␣ 2 -adrenoceptors in suicide victims with mood disorders is in accord with some, but not all, previous studies where radiolabeled agonists allowed the detection of increased ␣ 2 -adrenoceptor densities in postmortem brain areas. [8] [9] [10] [11] [12] 14 A lack of differences in the agonist radioligand binding density of ␣ 2 -adrenoceptors has also been reported between subjects with major depression and controls. 45, 46 The more rigorous diagnosis methodology (psychological autopsy vs searching of established medical records in the present study), the stricter inclusion and exclusion criteria, and the careful matching one-to-one reported herein could explain the apparent discrepancies between authors. Likewise, the present findings emphasize the proposed ␣ 2 -adrenoceptor supersensitivity in brain of depressed suicide victims by using a functional approach to the evaluation of receptor sensitivity. Although several ␣ 2 -adrenoceptor subtypes are expressed in human brain, 47, 48 the ␣ 2A -adrenoceptor subtype is the predominant one in frontal cortex. 48, 49 Therefore, the observed supersensitivity may reasonably be attributed to this adrenoceptor subtype 12 as recently confirmed by the presence of enhanced ␣ 2A -adrenoceptor protein immunoreactive levels in brains of depressed suicide victims. 13 Neurochemical alterations of 5-HT 1A serotonin receptors have been suggested to play a role in major depression and suicidality. However, clear evidence for an increased agonist binding density has been only demonstrated in the brainstem area 50 where 5-HT 1A serotonin receptors are located on dorsal and medial raphe neurons. 51 In contrast, most, but not all, studies in frontal cortex have reported no changes of postsynaptic 5-HT 1A serotonin receptors in depressed suicide victims. [52] [53] [54] [55] [56] [57] The present study agrees with these data and demonstrates the unaltered functional status of these postsynaptic 5-HT 1A serotonin receptors in suicide victims with mood disorders. Recently, a widespread reduction in 5-HT 1A serotonin receptor binding potential has been drawn from positron emission tomography analysis of 25 depressed patients (unmedicated or medicated) with the selective antagonist [
11 C]WAY-100635, 58 which could reflect either a reduction in the number of 5-HT 1A serotonin receptors or a decrease in receptor affinity. In previous receptor radioligand binding studies, the lack of changes in brain GABA B and muscarinic receptor densities of depressed suicides has been a consistent finding. [59] [60] [61] The density of -opioid receptors has been reported to be elevated in young 62, 63 but not in elderly 62 depressed suicide victims. The present study, comprising a distribution of subjects similar to the subgroup termed as old by Gross-Isseroff et al, 62 did not reveal differences in functional activity of -opioid receptors between suicide victims and controls.
Friedman and Wang 29 reported enhanced [ 35 S]GTP␥S binding responses to single concentrations of 5-HT, the ␤-adrenoceptor agonist isoproterenol and the muscarinic receptor agonist carbachol in the frontal cortex of five subjects with bipolar disorder. The preliminary findings were interpreted in congruence with the observed increase of heterotrimeric G-proteins, but the status of the receptor involved in the response was not explored (ie, delineation of full concentrationresponse curves to the agonists). Therefore, it is difficult to compare precisely such information with the present results.
Chronic antidepressant and lithium treatments have been repeatedly shown to induce downregulation and desensitization of ␣ 2 -adrenoceptors in platelets of depressed patients 20, 21, 64 and in rat brain. [15] [16] [17] 19, 65 In the human brain, chronic antidepressant treatment seems to downregulate ␣ 2A -adrenoceptors in depressed suicide victims. 11 Nevertheless, the enhanced immunoreactive levels of the ␣ 2A -adrenoceptor protein in depressed suicide victims remain more resistant to downregulation by antidepressants. 13 The present observations suggest a higher sensitivity (lower EC 50 values) of ␣ 2A -adrenoceptors in drug-free than in drugtreated suicide victims. Whatever the status of the subject, the sensitivity of ␣ 2A -adrenoceptors in suicide victims was higher than that in matched controls. It is possible that an insufficient treatment, 66, 67 patient compliance, 68 and pharmacokinetic (inadequate blood levels), or pharmacodynamic (lack of response) reasons could have contributed to the observed supersensitivity of ␣ 2A -adrenoceptors in suicide victims under treatment. On the other hand, the ability of lithium and antidepressant drugs to induce downregulation and desensitization of ␣ 2 -adrenoceptors makes it improbable that the ␣ 2A -adrenoceptor supersensitivity observed herein could be ascribed to the treatment with psychotropic drugs.
The increasing interest in the involvement of G-proteins in psychiatric disorders has yielded multiple findings in postmortem brain samples. An enhanced immunoreactivity of brain G ␣s -protein has been associated with bipolar disorders 27, 29, 69 and depression 28, 30 but evidence of unaltered G ␣s -protein levels has also been obtained, 26 even by the same groups. 70 Potential changes in G ␣1/2 -and G ␣o -protein levels occurring in brain of subjects with mood disorders have also been considered. Unaltered G ␣i1/2 -, G ␣o -protein immunoreactivity is the most often reported finding [26] [27] [28] [29] 69, 70 although propensity for decreased G ␣i2 30 and increased G ␣i1/2 13 have also been found. The small sample size 29 and the treatment with mood-stabilizing medications 70 might account for the discrepancies between and within groups. The present study did not find changes of G-protein immunoreactivity in a larger sample size of suicide victims and treatment-related alterations were not present. The role that ␣ 2A -adrenoceptors play in mood disorders may be related to the location of these receptors on noradrenergic and serotonergic neurons. Somatodendritic ␣ 2A -adrenoceptors on locus coeruleus cells regulate the firing activity of noradrenergic neurons and, consequently, the release of NE in projecting areas such as the frontal cortex. 71 A reduced number of noradrenergic neurons 72 associated with reduced NE transporter density, 73 elevated levels of tyrosine hydroxylase, 74, 75 and upregulation of ␣ 2A -adrenoceptors 14 have been found in the locus coeruleus of suicide and/or depressed subjects. In terminal areas, ␣ 2A -adrenoceptors are located as autoreceptors on noradrenergic terminals 7, 76 and as heteroreceptors on serotonergic terminals. 77 At these levels, ␣ 2A -adrenoceptors modulate the local release of NE and 5-HT from the respective terminals. Thus, the observed enhanced activity of presynaptic ␣ 2A -adrenoceptors in the frontal cortex of suicide victims with mood disorders could contribute to the diminished activity of noradrenergic and serotonergic neurons in these subjects. [78] [79] [80] [81] 
